
|Videos|April 26, 2023
EDS Evaluation
Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).
Advertisement
Episodes in this series

Advertisement
Related to this article

In a real-world cohort, tenecteplase before thrombectomy was associated with lower mortality and fewer new speech and movement deficits than alteplase, without an increase in symptomatic intracranial hemorrhage.

Karissa L. Gable, MD, and a pannel of clinicians discussed how targeted therapies are changing steroid use, bridging and treatment sequencing in generalized myasthenia gravis at an October 15, 2026, forum in Morrisville, North Carolina.

The FDA issued a second complete response letter for deramiocel in Duchenne muscular dystrophy, citing insufficient evidence of effectiveness from the phase 3 HOPE-3 trial.

Chris Favilla, MD, stroke neurologist at the University of Pennsylvania, discusses findings that cerebral venous sinus stenting improves arterial hemodynamics in patients with idiopathic intracranial hypertension (IIH) and what they mean for understanding the disease.

5-year findings from the Clarity AD long-term extension, presented at CTAD 2026, showed progressively greater differences in CDR-SB outcomes compared with external natural history cohorts.

Mitzi Joi Williams, MD, is joined by Temitope Adeyey, MD, and Chantale Branson, MD, to discuss headache and facial pain conditions beyond migraine.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Issues Second Complete Response Letter for Deramiocel in Duchenne Muscular Dystrophy
2
FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis
3
FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease
4
FDA Approves 2 gMG Treatments, AR1001 Slows Decline in Monotherapy Group of POLARIS-AD Trial, Benjamin Greenberg's, MD, MHS, Insights From the 2026 RNDS
5













